Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.42 USD
Change Today +0.12 / 1.06%
Volume 438.4K
BCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$11.29
Previous Close
$11.30
Day High
$11.50
Day Low
$11.15
52 Week High
08/11/14 - $14.62
52 Week Low
03/26/15 - $7.85
Market Cap
828.2M
Average Volume 10 Days
638.6K
EPS TTM
$-0.67
Shares Outstanding
72.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

50 Employees
Last Reported Date: 03/2/15
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $633.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $461.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $503.8K
Senior Vice President of Drug Discovery
Total Annual Compensation: $460.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2014.

biocryst pharmaceuticals inc (BCRX) Key Developments

BioCryst Pharmaceuticals, Inc. Announces Initiation of A Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. Discovered by BioCryst, BCX7353 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). BioCryst has successfully completed nonclinical safety studies, as well as in vitro studies in which BCX7353 exhibited potent and selective inhibition of plasma kallikrein. The pharmacokinetic profile of BCX7353 in preclinical studies indicates its potential for once daily dosing.

BioCryst Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Operating Outlook for the Year 2015

BioCryst Pharmaceuticals, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were USD 6,826,000 against USD 3,458,000 a year ago. Loss from operations was USD 14,430,000 against USD 7,386,000 a year ago. Net loss was USD 15,164,000 against USD 10,137,000 a year ago. Basic and diluted net loss per common share was USD 0.21 against USD 0.17 a year ago. Net operating cash use for the first quarter of 2015 was USD 3.8 million, as compared to USD 5.0 million for the first quarter of 2014. The increase in revenue was primarily associated with higher collaborative revenue associated with BCX4430 development under an early development contract with the National Institute of Allergy and Infectious Diseases (NIAID) and the recently awarded advanced development contract with the Biomedical Advanced Research and Development Authority (BARDA/HHS). The company expect operating outlook for 2015 to be unchanged from guidance issued in February. Based upon development plans and assumptions and awarded government contracts, the company expects its 2015 net operating cash use to be in the range of USD 65 million to USD 80 million.

BioCryst Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 02:20 PM

BioCryst Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 02:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Jon P. Stonehouse, Chief Executive Officer, President and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $11.42 USD +0.12

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,335 JPY 0.00
Dyax Corp $26.71 USD -0.06
GlaxoSmithKline PLC 1,465 GBp +14.00
Pharming Group NV €0.32 EUR +0.001
Shire PLC 5,540 GBp +35.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.7x
Price/Book 12.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 43.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.